0
Larimar Therapeutics, Inc. Banner Image

Larimar Therapeutics, Inc.

  • Ticker LRMR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Larimar Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Bala Cynwyd, Pennsylvania
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platformMore to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Larimar Therapeutics, Inc.

Most Recent Annual Report

Larimar Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K
Larimar Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!